10.71
0.35 (3.38%)
| Penutupan Terdahulu | 10.36 |
| Buka | 10.29 |
| Jumlah Dagangan | 175,796 |
| Purata Dagangan (3B) | 185,157 |
| Modal Pasaran | 312,544,704 |
| Harga / Jualan (P/S) | 11.15 |
| Harga / Buku (P/B) | 1.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| EPS Cair (TTM) | -2.49 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.25% |
| Nisbah Semasa (MRQ) | 21.47 |
| Aliran Tunai Operasi (OCF TTM) | -39.28 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.34 M |
| Pulangan Atas Aset (ROA TTM) | -22.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Contineum Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.75 |
|
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.82% |
| % Dimiliki oleh Institusi | 79.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sectoral Asset Management Inc | 30 Sep 2025 | 800,787 |
| Red Tree Management, Llc | 30 Sep 2025 | 638,158 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 22.00 (RBC Capital, 105.42%) | Beli |
| Median | 20.00 (86.74%) | |
| Rendah | 14.00 (Baird, 30.72%) | Beli |
| Purata | 18.67 (74.32%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 10.72 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 24 Nov 2025 | 14.00 (30.72%) | Beli | 10.36 |
| RBC Capital | 21 Nov 2025 | 22.00 (105.42%) | Beli | 10.95 |
| Leerink Partners | 25 Sep 2025 | 20.00 (86.74%) | Beli | 10.86 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Nov 2025 | Pengumuman | Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference |
| 20 Nov 2025 | Pengumuman | Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) |
| 30 Oct 2025 | Pengumuman | Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones |
| 18 Sep 2025 | Pengumuman | Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |